2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal For ImmunoTherapy Of Cancer 2022, 10: e003956. PMID: 35640927, PMCID: PMC9157337, DOI: 10.1136/jitc-2021-003956.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSmall cell lung cancerClinical practice guidelinesLung cancerQuality of lifePractice guidelinesTreatment of NSCLCImmune-related adverse eventsCancer clinical practice guidelinesLung cancer careImmune checkpoint inhibitorsUse of immunotherapyFirst-line therapySubset of patientsCell lung cancerCancer care providersImmunotherapy of cancerConsensus-based recommendationsAdjuvant settingAdvanced diseaseCheckpoint inhibitorsAdverse eventsDurable responsesThoracic malignanciesAutoimmune disorders
2006
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer
Fehrenbacher L, O’Neill V, Belani C, Bonomi P, Hart L, Melnyk O, Sandler A, Ramies D, Herbst R. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Journal Of Clinical Oncology 2006, 24: 7062-7062. DOI: 10.1200/jco.2006.24.18_suppl.7062.Peer-Reviewed Original ResearchDisease progressionArm 1Single-arm phase I/II studyRefractory non-small cell lung cancerPhase I/II studyNon-small cell lung cancerRandomized phase II trialEGFR tyrosine kinase inhibitorsAnti-VEGF mAbsPlatinum-based regimenSafety of bevacizumabCombination of bevacizumabFirst-line settingNon-squamous NSCLCAdvanced stage diseaseAvailable EGFR tyrosine kinase inhibitorsPhase II trialProgression-free survivalTreatment of recurrentCell lung cancerClinical disease progressionFavorable safety profileTreatment of NSCLCTyrosine kinase inhibitorsAdenocarcinoma/
2002
ZD1839 (Iressa™) in Non-Small Cell Lung Cancer
Herbst RS, Kies MS. ZD1839 (Iressa™) in Non-Small Cell Lung Cancer. The Oncologist 2002, 7: 9-15. PMID: 12202783, DOI: 10.1634/theoncologist.7-suppl_4-9.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerAdvanced non-small cell lung cancerEGFR tyrosine kinase inhibitor ZD1839Treatment of NSCLCCisplatin-based combination chemotherapyAnti-EGFR agentsConventional cytotoxic chemotherapyAvailable clinical dataGrowth factor receptorCombination chemotherapyCytotoxic chemotherapyPatient populationClinical dataClinical developmentGreater efficacyFactor receptorZD1839Less toxicityUseful targetChemotherapyCancerPrognosisTargeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer
Herbst RS. Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer. Clinical Lung Cancer 2002, 3: s30-s38. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.Peer-Reviewed Original ResearchCell lung cancerVascular endothelial growth factorProtein kinase C inhibitorLung cancerKinase C inhibitorSpecific cellular mechanismsCell cycle inhibitionEGFR tyrosine kinaseSignal transductionTyrosine kinaseKey enzymeReceptor-targeted therapyTreatment of NSCLCTumor growth delayC inhibitorEndothelial growth factorCellular mechanismsOSI-774IMC-C225Advanced NSCLCPoor prognosisMajor classesTargeted therapyNovel agentsTherapeutic improvement
1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Herbst RS, Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. Seminars In Oncology 1999, 26: 67-70; discussion 71-2. PMID: 10585011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerVinorelbine/gemcitabineCell lung cancerMedian survivalSurvival rateStable diseasePartial responseLung cancerDisease progressionDay 1Treatment of NSCLCStandard platinum-based regimensGemcitabine/vinorelbineChemotherapy-naive patientsPerformance status 0Treatment-naive patientsPhase II studyPlatinum-based regimensCombination of vinorelbineMedian survival timeOverall response rateNonplatinum agentsStatus 0Vinorelbine combination